GlassScriptPhysician profile
Vincent L Anthony
NPI 1396851903
$6,397.57
in general payments reported to CMS, 2019-2025
23 companies · $948 in 2025
The $948 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $546 · 2021: $563 · 2022: $975 · 2023: $1,288 · 2024: $1,553 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,720 · Education: $68.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,719.99 |
| Education | $68.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $1,501.80 | 2019-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $764.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $597.81 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Fresenius USA Marketing, INC. | $418.36 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $370.04 | 2019-2025 | Krystexxa, Repatha |
| Mallinckrodt Hospital Products INC. | $341.60 | 2021-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $313.54 | 2019-2025 | Voyxact |
| Horizon Therapeutics Plc | $289.20 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $253.82 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.02 | 2025 | Jardiance |
| Ardelyx, INC. | $202.92 | 2023-2024 | Ibsrela |
| Novo Nordisk INC | $198.28 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Gilead Sciences, INC. | $170.63 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $170.45 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $140.43 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $128.31 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $82.67 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Opko Pharmaceuticals, LLC | $76.69 | 2024-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $70.79 | 2023-2024 | Benlysta, Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $23.61 | 2019 | |
| Boston Scientific Corporation | $21.51 | 2024 | |
| Travere Therapeutics, INC. | $19.10 | 2023 | |
| Rockwell Medical, INC. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.